List view / Grid view
14 March 2014 | By Novo Nordisk
Novo Nordisk is increasing its drug development capacity by investing 550 million Danish kroner in a new research and development facility in Bagsværd, Denmark...
27 February 2014 | By Novo Nordisk
The employees of Novo Nordisk A/S have conducted the election of employee representatives to the Board of Directors of Novo Nordisk A/S...
20 January 2014 | By Novo Nordisk
Canada is the first country to make NovoFine® Plus available and will be followed by several other countries during 2014 and 2015...
10 December 2013 | By Novo Nordisk
The reporting relates to the company’s receipt of a Complete Response Letter from the US Food and Drug Administration...
3 December 2013 | By Novo Nordisk
Data presented at the World Diabetes Congress of the International Diabetes Federation show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia...
3 December 2013 | By Novo Nordisk
New phase 3 data from the investigational therapy IDegLira were presented at the World Diabetes Congress of the International Diabetes Federation...
22 November 2013 | By Novo Nordisk
Insulin aspart PumpCart® is a 1.6 ml prefilled insulin pump cartridge containing the rapid-acting insulin aspart...
18 November 2013 | By Novo Nordisk
NovoEight® has passed the review by the Committee on Drugs of Japan's Pharmaceutical Affairs and Sanitation Council...
1 November 2013 | By Novo Nordisk
FlexTouch® is the latest innovation in prefilled insulin delivery systems from Novo Nordisk...
31 October 2013 | By Novo Nordisk
Sales growth of 8% driven by Victoza®, Levemir® og NovoRapid®...
16 October 2013 | By Novo Nordisk
“The approval of Novoeight® marks an important step in offering a new alternative for people with haemophilia A..."
27 September 2013 | By Novo Nordisk
Data from the DUAL™ I trial show IDegLira demonstrates a statistically significant greater reduction in blood sugar levels (HbA1c) compared to insulin degludec or liraglutide alone...
25 September 2013 | By Novo Nordisk
Recruitment for the LEADER® trial assessing cardiovascular (CV) outcomes of the once-daily GLP-1 analogue, Victoza®, completed in April 2012, resulted in a high-risk population with patient numbers exceeding the original target...
20 September 2013 | By Novo Nordisk
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion on its recombinant factor VIII product turoctocog alfa, with the intended brand name NovoEight®...
8 August 2013 | By Novo Nordisk
Sales growth of 11% driven by Victoza®, NovoRapid® and Levemir®...
